Clinical toxicologic and pharmacologic studies of gallium nitrate

Cancer. 1979 Nov;44(5):1722-7. doi: 10.1002/1097-0142(197911)44:5<1722::aid-cncr2820440528>3.0.co;2-c.

Abstract

Gallium nitrate, administered intravenously to patients with advanced cancer, produced renal functional abnormalities consistently at a dose of 750 mg/m2. The toxicity at that dose could be modified by fluid loading and osmotic diuresis. Pharmacokinetic studies revealed a biphasic half-life, (T 1/2 alpha = 87 minutes and T 1/2 beta = 24.5 hours). Osmotic diuresis reduced the urinary concentration of gallium but did not affect serum levels or clearance.

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anemia / chemically induced
  • Calcium / urine
  • Clinical Trials as Topic
  • Diuresis
  • Gallium / administration & dosage
  • Gallium / metabolism
  • Gallium / toxicity*
  • Humans
  • Kidney / drug effects*
  • Mannitol / administration & dosage
  • Neoplasms / drug therapy
  • Neoplasms / metabolism

Substances

  • Mannitol
  • Gallium
  • Calcium